UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer Yu SunakawaWataru IchikawaYasutsuna Sasaki Original Article 19 October 2010 Pages: 279 - 284
Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability Kyu-pyo KimMin-Hee RyuYoon-Koo Kang Original Article 19 October 2010 Pages: 285 - 291
A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors Matthew H. KulkeJennifer A. ChanCharles S. Fuchs Original Article 20 October 2010 Pages: 293 - 300
Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy Kohei ShitaraKeitaro MatsuoKei Muro Original Article 20 October 2010 Pages: 301 - 307
Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer? Ahmet BiliciBala Basak Oven UstaaliogluMahmut Gumus Original Article 22 October 2010 Pages: 309 - 316
Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX Myung Hee ChangIn Kyu LeeJae Ho Byun Original Article 24 October 2010 Pages: 317 - 323
The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention Susan K. PeirceHarry W. FindleyDonald L. Durden Original Article Open access 24 October 2010 Pages: 325 - 335
Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy Maki TaniokaNoriyuki KatsumataYasuhiro Fujiwara Original Article 26 October 2010 Pages: 337 - 342
Experiment on enhancing antitumor effect of intravenous epirubicin hydrochloride by acoustic cavitation in situ combined with phospholipid-based microbubbles Cui-Tao LuYing-Zheng ZhaoLu Zhang Original Article 27 October 2010 Pages: 343 - 348
Anticancer effect of (E)-2-hydroxy-3′,4,5′-trimethoxystilbene on breast cancer cells by mitochondrial depolarization Yee Soo ChaeJong Gwang KimHoyong Park Original Article 27 October 2010 Pages: 349 - 358
Conjugation of chlorin p 6 to histamine enhances its cellular uptake and phototoxicity in oral cancer cells Arpana PariharAlok DubeP. K. Gupta Original Article 27 October 2010 Pages: 359 - 369
Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors Yuan YuanDeirdre J. CohenHoward S. Hochster Original Article 27 October 2010 Pages: 371 - 378
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer Allyson J. OceanPaul ChristosMaureen E. Lane Original Article 28 October 2010 Pages: 379 - 388
The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models Young-Soon NaKyung-Ah JungTae Won Kim Original Article 03 November 2010 Pages: 389 - 398
Lack of in vivo cross-resistance with 4′-thio-ara-C against drug-resistant murine P388 and L1210 leukemias William R. WaudKaren S. GilbertJohn A. Secrist III Original Article 11 November 2010 Pages: 399 - 403
Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase Yon Hui KimAmy CoonGarth Powis Original Article 11 November 2010 Pages: 405 - 413
A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer Athanasios KotsakisSophia AgelakiVassilis Georgoulias Original Article 11 November 2010 Pages: 415 - 422
Clinical benefit of early phase clinical trial participation for advanced sarcoma patients Robin L. JonesDavid OlmosIan R. Judson Original Article 11 November 2010 Pages: 423 - 429
The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations Antonia TsallasJohn JacksonHelen Burt Original Article 11 November 2010 Pages: 431 - 444
Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice Yasmine S. TouilJohanne SeguinGuy G. Chabot Original Article 11 November 2010 Pages: 445 - 455
Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer Eleni AndreopoulouThomas ChenFranco Muggia Original Article 11 November 2010 Pages: 457 - 463
Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling Beom Soo ShinJürgen B. BulittaSun Dong Yoo Original Article 11 November 2010 Pages: 465 - 475
Cytotoxic responses to N-(4-hydroxyphenyl)retinamide in human pancreatic cancer cells Maria C. MessnerMyles C. Cabot Original Article 12 November 2010 Pages: 477 - 487
Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells Li-Yuan BaiHany A. OmarJing-Ru Weng Original Article 12 November 2010 Pages: 489 - 496
The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice Trung The VanMasaki HanibuchiSaburo Sone Original Article Open access 16 November 2010 Pages: 497 - 504
Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors M. TaniokaH. NokiharaT. Tamura Original Article 16 November 2010 Pages: 505 - 511
Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination Lee JiaGregory S. GormanCraig W. Beattie Original Article 18 November 2010 Pages: 513 - 524
Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography–tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity Muhittin A. SerdarErdim SertoğluMurat Cihan Original Article 24 November 2010 Pages: 525 - 529
Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats Jong-Mu SunMi Hyun NamMyung-Ju Ahn Original Article 25 November 2010 Pages: 531 - 538
PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma Ghassan K. Abou-AlfaStephan L. ChanChao-Jung Tsao Clinical Trial Report 19 May 2011 Pages: 539 - 545
Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer Peter D. BoasbergCharles H. RedfernAlejandro D. Ricart Short Communication 24 April 2011 Pages: 547 - 552